- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.04. | Dividendenbekanntmachungen (12.04.2024) | 10.953 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,55 USD 0,5127 EUR ABBVIE INC US00287Y1091 1,55 USD 1,4449 EUR ABBVIE INC CDR CA00288K1084 0... ► Artikel lesen | |
| 29.03. | Fortress Biotech Inc reports results for the quarter ended in December - Earnings Summary | 6 | Reuters | ||
| 28.03. | Fortress Biotech GAAP EPS of -$8.47 beats by $0.64, revenue of $84.51M beats by $4.83M | 7 | Seeking Alpha | ||
| 28.03. | Fortress Biotech, Inc.: Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights | 2.026 | GlobeNewswire (Europe) | Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing... ► Artikel lesen | |
| 28.03. | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.03. | Fortress Biotech shares upgraded with $10 price target | 6 | Investing.com | ||
| 14.03. | Dividendenbekanntmachungen (14.03.2024) | 10.200 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| 12.03. | Fortress Biotech, Inc.: Fortress Biotech to Participate in 36th Annual ROTH Conference | 1 | GlobeNewswire (USA) | ||
| 04.03. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease | 123 | GlobeNewswire (Europe) | Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for Menkes disease Cyprium Therapeutics, a majority-owned... ► Artikel lesen | |
| 14.02. | Dividendenbekanntmachungen (14.02.2024) | 4.479 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AFFILIATED MANAGERS GROUP INC US0082521081 0,01 USD 0,0093 EUR AGCO CORPORATION US0010841023 0,29 USD 0,2707 EUR ALLEGIANT TRAVEL... ► Artikel lesen | |
| 13.02. | Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 goes ex dividend tomorrow | 5 | Seeking Alpha | ||
| 26.01. | Fortress Biotech, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 11.01. | Dividendenbekanntmachungen (11.01.2024) | 2.395 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,55 USD 0,5012 EUR ADVANCE AUTO PARTS INC US00751Y1064 0,25 USD 0,2278 EUR AMERICAN FINANCIAL... ► Artikel lesen | |
| 10.01. | Fortress Biotech 9.375% CUM PFD A goes ex-dividend tomorrow | 11 | Seeking Alpha | ||
| 03.01. | Fortress Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 03.01. | Fortress Biotech, Inc.: Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 7 | GlobeNewswire (USA) | ||
| 29.12.23 | Nasdaq Down Over 100 Points; Fortress Biotech Shares Plummet | 6 | Benzinga.com | ||
| 29.12.23 | Why Fortress Biotech Shares Are Tumbling Today | 5 | Benzinga.com | ||
| 29.12.23 | Fortress Biotech Announces Pricing Of Registered Direct Offering | 4 | RTTNews | ||
| 29.12.23 | Fortress Biotech drops on plans to issue 3.3M shares | 1 | Seeking Alpha |
Seite:
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 46,840 | +0,32 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN | STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 25,800 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| KEROS THERAPEUTICS | 57,72 | 0,00 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| IMMUNOVANT | 28,520 | 0,00 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
| ARVINAS | 32,480 | +2,23 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 36,240 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session Nello Mainolfi, Founder, President... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,740 | +2,45 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| JANUX THERAPEUTICS | 58,19 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| VERA THERAPEUTICS | 42,310 | +7,09 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,340 | 0,00 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| COGENT BIOSCIENCES | 6,910 | +6,31 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor | WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 28,100 | +4,04 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| CABALETTA BIO | 12,410 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,830 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| NUVALENT | 70,65 | +2,57 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |
FORTRESS BIOTECH INC PREF gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 13,600 Euro und damit +7,09 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 2,16 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von +15,90 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
